HIV Transmission Rate Modeling: a Primer, Review, and Extension

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2011 Sep 20

PMID 21928097

Citations 9

Authors

Steven D Pinkerton

Affiliations

Soon will be listed here.

Abstract

Several mathematical modeling studies based on the concept of "HIV transmission rates" have recently appeared in the literature. The transmission rate for a particular group of HIV-infected persons is defined as the mean number of secondary infections per member of the group per unit time. This article reviews the fundamental principles and mathematics of transmission rate models; explicates the relationship between these models, Bernoullian models of HIV transmission, and mathematical models based on the concept of the "reproductive rate of infection"; describes an extension of existing transmission rate models to better incorporate the positive impact of HIV treatment; and discusses the limitations of the transmission rate modeling approach. Results from the extended transmission rate model indicate that approximately 51.6% of new sexually-transmitted infections in the US are due to the transmission risk behaviors of infected persons who are unaware of their infection, including 10.9% due to persons in the acute phase of HIV infection. Findings from this study suggest that significant reductions in HIV incidence likely will require a combination of increased antibody testing, enhanced early detection of acute HIV infection, appropriate medical care and antiretroviral medicine adherence counseling, and behavioral risk reduction interventions.

Citing Articles

Assessment of the Cost-Effectiveness of a Brief Video Intervention for Sexually Transmitted Disease Prevention.

Williams A, Gift T, ODonnell L, Rietmeijer C, Malotte C, Margolis A Sex Transm Dis. 2019; 47(2):130-135.

PMID: 31834206 PMC: 7590367. DOI: 10.1097/OLQ.0000000000001109.

Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review.

Zang X, Krebs E, Wang L, Marshall B, Granich R, Schackman B Pharmacoeconomics. 2019; 37(10):1219-1239.

PMID: 31222521 PMC: 6711792. DOI: 10.1007/s40273-019-00817-1.

Estimating epidemiological parameters of a stochastic differential model of HIV dynamics using hierarchical Bayesian statistics.

Dale R, Guo B PLoS One. 2018; 13(7):e0200126.

PMID: 30044818 PMC: 6059410. DOI: 10.1371/journal.pone.0200126.

Clinical and Economic Effects of a Pharmacist-Administered Antiretroviral Therapy Adherence Clinic for Patients Living with HIV.

Dilworth T, Klein P, Mercier R, Borrego M, Jakeman B, Pinkerton S J Manag Care Spec Pharm. 2018; 24(2):165-172.

PMID: 29384024 PMC: 6528483. DOI: 10.18553/jmcp.2018.24.2.165.

Posterior Estimates of Dynamic Constants in HIV Transmission Modeling.

Chen Y, Dale R, He H, Le Q Comput Math Methods Med. 2017; 2017:1093045.

PMID: 29250132 PMC: 5698610. DOI: 10.1155/2017/1093045.

References

. HIV surveillance--United States, 1981-2008. MMWR Morb Mortal Wkly Rep. 2011; 60(21):689-93. View

Holtgrave D, Anderson T . Utilizing HIV transmission rates to assist in prioritizing HIV prevention services. Int J STD AIDS. 2004; 15(12):789-92. DOI: 10.1258/0956462042563639. View

Holtgrave D . Estimation of annual HIV transmission rates in the United States, 1978-2000. J Acquir Immune Defic Syndr. 2004; 35(1):89-92. DOI: 10.1097/00126334-200401010-00013. View

Prabhu V, Hutchinson A, Farnham P, Sansom S . Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS. 2009; 23(13):1792-4. DOI: 10.1097/QAD.0b013e32832e7d04. View

Hutchinson A, Patel P, Sansom S, Farnham P, Sullivan T, Bennett B . Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med. 2010; 7(9):e1000342. PMC: 2946951. DOI: 10.1371/journal.pmed.1000342. View

Dieffenbach C, Fauci A . Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009; 301(22):2380-2. DOI: 10.1001/jama.2009.828. View

Marks G, Crepaz N, Senterfitt J, Janssen R . Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005; 39(4):446-53. DOI: 10.1097/01.qai.0000151079.33935.79. View

Pinkerton S, Kibicho J, Galletly C . Is the US AIDS drug assistance program cost-effective?. AIDS Behav. 2012; 17(1):1-4. PMC: 4103006. DOI: 10.1007/s10461-012-0321-z. View

Branson B, Handsfield H, Lampe M, Janssen R, Taylor A, Lyss S . Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006; 55(RR-14):1-17. View

10.

Holtgrave D, Hall H, Rhodes P, Wolitski R . Updated annual HIV transmission rates in the United States, 1977-2006. J Acquir Immune Defic Syndr. 2009; 50(2):236-8. DOI: 10.1097/qai.0b013e31819001be. View

11.

Hall H, Song R, Rhodes P, Prejean J, An Q, Lee L . Estimation of HIV incidence in the United States. JAMA. 2008; 300(5):520-9. PMC: 2919237. DOI: 10.1001/jama.300.5.520. View

12.

Pinkerton S . How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission?. AIDS. 2007; 21(12):1625-9. PMC: 2377417. DOI: 10.1097/QAD.0b013e32826fb6a6. View

13.

Pinkerton S, Holtgrave D, Galletly C . Infections prevented by increasing HIV serostatus awareness in the United States, 2001 to 2004. J Acquir Immune Defic Syndr. 2008; 47(3):354-7. PMC: 2408958. DOI: 10.1097/QAI.0b013e318160d57e. View

14.

Millett G, Crowley J, Koh H, Valdiserri R, Frieden T, Dieffenbach C . A way forward: the National HIV/AIDS Strategy and reducing HIV incidence in the United States. J Acquir Immune Defic Syndr. 2011; 55 Suppl 2:S144-7. DOI: 10.1097/QAI.0b013e3181fbcb04. View

15.

Hall H, Green T, Wolitski R, Holtgrave D, Rhodes P, Lehman J . Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr. 2010; 55(2):271-6. DOI: 10.1097/QAI.0b013e3181e8f90c. View

16.

Lansky A, Brooks J, DiNenno E, Heffelfinger J, Hall H, Mermin J . Epidemiology of HIV in the United States. J Acquir Immune Defic Syndr. 2011; 55 Suppl 2:S64-8. DOI: 10.1097/QAI.0b013e3181fbbe15. View

17.

Anderson R, May R . Epidemiological parameters of HIV transmission. Nature. 1988; 333(6173):514-9. DOI: 10.1038/333514a0. View

18.

Holtgrave D . Is the elimination of HIV infection within reach in the United States? Lessons from an epidemiologic transmission model. Public Health Rep. 2010; 125(3):372-6. PMC: 2848261. DOI: 10.1177/003335491012500305. View

19.

Fenton K . Changing epidemiology of HIV/AIDS in the United States: implications for enhancing and promoting HIV testing strategies. Clin Infect Dis. 2008; 45 Suppl 4:S213-20. DOI: 10.1086/522615. View

20.

Holtgrave D . Potential and limitations of a 'test and treat' strategy as HIV prevention in the United States. Int J Clin Pract. 2010; 64(6):678-81. DOI: 10.1111/j.1742-1241.2010.02381.x. View